An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether rivaroxaban in addition to standard care
reduces the risk of the composite of cardiovascular death, myocardial infarction, or stroke
in patients with a recent acute coronary syndrome compared with placebo.
Phase:
Phase 3
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.